Repeated Intradetrusor Application of Botulinum Toxin A in Children with Detrusor Overactivity

Czech version

Authors: P. Zerhau ¹; M. Husár ¹; E. Brichtová ²; Z. Mackerle ²; O. Šmakal ³; J. Vrána ³
Authors‘ workplace: Odd. dětské urologie, Klinika dětské chirurgie, ortopedie a traumatologie LF MU a FN Brno ¹; Odd. dětské neurochirurgie, Klinika dětské chirurgie, ortopedie a traumatologie LF MU a FN Brno ²; Urologická klinika LF UP a FN Olomouc ³
Published in: Cesk Slov Neurol N 2011; 74/107(4): 471-474
Category: Short Communication

Overview

Objective:
Analysis of therapy by repeated intradetrusor application of botulinum toxin A in children’s urinary bladder detrusor overactivity. Material and methods: The study included a total of 17 patients between the ages of 6 and 14 years (mean 9.5, median 9). Eight of them were treated for neurogenic detrusor overactivity (Group I: 4 girls and 4 boys), and nine for non-neurogenic detrusor overactivity (Group II: 3 girls and 6 boys). Botulinum toxin A at a dose of 10 to 12 IU/ kg, in proportion to body weight, was applied endoscopically. Nine patients were treated twice, the others two or three times 6 months after previous injection in every case. Both urodynamic data and bladder diary data were assessed 1, 3, and 6 months after each application. Results: 11 patients (65%) showed improved urine continence while 2 (11%) of patients exhibited full extinction of incontinence. Extinction and/or reduction of non-inhibited detrusor contractions always culminated in the third month after application. No one child demonstrated a change of miction regime or need for catheterisation. Maximum increase of cystometric capacity took effect after 3 months: in Group I by 55% (107 ±76 ml; p = 0.0068), in Group II by 40% (72 ±41 ml; p = 0.0010). The degree of greatest decrease of maximum detrusor pressure was: Group I by 49% (29 ±11.2 cm H₂O; p = 0.0126) three months after application; Group II by 64% (45 ±16.5 cm H₂O; p = 0.0069), one month after second application. No adverse effects emerged during treatment. Conclusion: Intradetrusor application of botulinum toxin A appears to be a safe and efficient treatment for detrusor overactivity in children, regardless of its origin. Repeated application does not potentiate the effect of this treatment.

Key words:
neurogenic bladder – botulinum toxin A – detrusor overactivity – incontinence

Sources

1. Kaňovský P.Cervikální dystonie. Cesk Slov Neurol N 2007, 70/103(4): 358–370.

2. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor sphincter dyssynergia in spinal cord injury patients. J Urol 1988, 139(5): 919–922.

3. Schurch R, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients – a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164(1): 692–697.

4. Krhut J, Zachoval R, Hradílek P, Havránek O, Zapletalová O. Botulotoxin v léčbě detruzorové hyperaktivity u pacientek s roztroušenou sklerózou. Cesk Slov Neurol N 2008; 71/104(4): 429–434.

5. Schulte-Baukloh H, Michael T, Schubert J, Stolze T, Knispel HH. Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002; 59(3): 325–328.

6. Krhut J, Kopecký J, Mainer K. Transuretrální injekce botulinumtoxinu v léčbě neurogenní hyperaktivity detruzoru. Čes Urol 2003, 7(1): 29–32

7. Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004; 171/2(1): 845–848.

8. Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol 2006; 175/3(1): 1102–1105.

9. Chenet A, Perrouin-Verbe B, Le Normand L, Labat JJ, Brunel P, Lefort M et al. Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity. Ann Readapt Med Phys 2007, 50(8): 651–660.

10. Do Ngoc Thanh C, Audry G, Forin V. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases. J Pediatr Urol 2009, 5(6): 430–436.

11. Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P et al. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 2006; 176(1): 328–331.